33.17

0.21% 0.07

Pre-market: 33.17

Cogent Biosciences Inc (COGT)

Overview News Price History Option Chain Financials Discussions Forecast Stock Split

Cogent Biosciences Inc stock is traded at $33.17, with a volume of 1.97M. It is up +0.21% in the last 24 hours and up +1.50% over the past month. Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with dependence on oncogenic KIT signaling.

Previous Close:

$33.10

Open:

$33.4

24h Volume:

1.97M

Relative Volume:

0.92

Market Cap:

$5.67B

Revenue:

Net Income/Loss:

$-354.30M

P/E Ratio:

-13.14

EPS:

-2.5234

Net Cash Flow:

$-286.27M

1W Performance:

+6.45%

1M Performance:

+1.50%

6M Performance:

-17.57%

1Y Performance:

+368.50%

1-Day Range:

$33.05

$33.86

1-Week Range:

$30.93

$33.86

52-Week Range:

$6.92

$43.73

Cogent Biosciences Inc Stock (COGT) Company Profile

Name

Cogent Biosciences Inc

Sector

Healthcare (1104)

Industry

Biotechnology (621)

Phone

617-945-5576

Address

275 WYMAN STREET, WALTHAM

Employee

258

Twitter

Next Earnings Date

2026-08-04

Latest SEC Filings

COGT's Discussions on Twitter

Compare COGT vs VRTX, REGN, ARGX, ALNY, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
COGT Cogent Biosciences Inc	33.17	5.67B	0	-354.30M	-286.27M	-2.5234
VRTX Vertex Pharmaceuticals Inc	450.46	114.33B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	614.98	64.47B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	884.20	54.99B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	287.80	38.42B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	160.06	34.03B	742.00K	-1.37B	-1.07B	-7.0731

Cogent Biosciences Inc Stock (COGT) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Mar-16-26	Resumed	Jefferies	Buy
Nov-10-25	Upgrade	Stifel	Hold → Buy
Nov-10-25	Upgrade	Wedbush	Neutral → Outperform
Oct-16-25	Initiated	Stifel	Hold
Sep-03-25	Initiated	Raymond James	Strong Buy
Mar-07-25	Initiated	Scotiabank	Sector Outperform
Dec-11-24	Downgrade	Needham	Buy → Hold
Feb-26-24	Downgrade	Robert W. Baird	Outperform → Neutral
Feb-08-24	Initiated	Citigroup	Buy
Dec-11-23	Downgrade	Wedbush	Outperform → Neutral
Dec-08-23	Initiated	JP Morgan	Overweight
Apr-28-23	Initiated	Robert W. Baird	Outperform
Mar-27-23	Resumed	H.C. Wainwright	Buy
Dec-14-22	Initiated	Needham	Buy
Jun-28-22	Initiated	Guggenheim	Buy
Oct-11-21	Initiated	H.C. Wainwright	Buy
Jun-09-21	Resumed	Jefferies	Buy
Dec-23-20	Initiated	Piper Sandler	Overweight
Oct-14-20	Initiated	Ladenburg Thalmann	Buy

View All

Cogent Biosciences Inc Stock (COGT) Latest News

Jun 15, 2026

Stifel reiterates Cogent stock Buy rating after trial data - Investing.com UK

Jun 15, 2026

Stifel reiterates Cogent stock Buy rating after trial data By Investing.com - Investing.com India

Jun 15, 2026

Jun 14, 2026

Cogent Biosciences: A Pre-Commercial Biotech With Commercial-Stage Leverage (NASDAQ:COGT) - Seeking Alpha

Jun 14, 2026

Jun 13, 2026